Logo

massively parallel sequencing

Research Triangle Institute Partners With GeneDx, Illumina for Expanded Newborn Screening Study

The study will offer whole-genome sequencing and genetic risk scores for type 1 diabetes for newborns born in North Carolina.

Life Sciences Tools Firms, Observers Sound Alarm on Near-Term China Business Outlook
Premium

Business in China is not going as well as expected for many US companies, especially those selling sequencing- and mass spec-related research tools.

NGS Firms Pursue Slice of Low-Throughput Market
Premium

Bigger isn't always better, as Singular Genomics, MGI Tech, and now Element build out product lines for smaller-scale sequencing. But are they going small enough?

Illumina, Pillar Biosciences Ink Global Distribution Agreement for Cancer Dx Assays

The firms said their distribution deal will facilitate the integration of Pillar's precision oncology assays and Illumina's sequencers.

Following CEO's Resignation, Questions Arise About Illumina's Future Direction
Premium

Francis deSouza's sudden departure over his signature Grail deal leaves analysts and customers wondering what's next for Illumina.

Apr 27, 2023

Illumina Sequencers Face Cybersecurity Vulnerability, FDA Warns

Mar 10, 2023

To Q40 and Beyond: Sequencing's Accuracy Revolution is Happening Now
Premium

Feb 21, 2023

Massively Parallel Reporter Assay Opens Door to Studying Cell Type-Specific Gene Regulation
Premium

Jan 13, 2023

Element Biosciences Points to First Wave of Customer Data at JP Morgan Conference

Jan 5, 2023

Sequencing Instrument Launches in 2022 Portend Heated Competition
Premium

Nov 16, 2022

Genome Insight, Seoul National University Hospital Collaborate on WGS Study of Pediatric Cancer Dx

Nov 10, 2022

Arima Genomics Inks Distribution Deals in Asia-Pacific Region

Nov 8, 2022

Singular Genomics Inks Sample Prep Partnerships With Paragon Genomics, Claret Bioscience; Reports Q3

Oct 18, 2022

Illumina, GenoScreen Partner to Comarket Genomic Testing for Multidrug-Resistant TB

Oct 11, 2022

Intermountain Forensics Partners with Astrea Forensics to Validate Sample Prep Technology

Sep 29, 2022

Illumina Strikes Back: New NovaSeq X Series Sequencers to Push Boundaries on Throughput, Cost
Premium

Sep 15, 2022

Broad Institute Study Evaluates Ultima Genomics Sequencer for Single-Cell RNA-Seq
Premium

Aug 19, 2022

High-Throughput Testing Reveals Genetic Programs, Pathogenic Variants in Neurodegenerative Disease

Aug 17, 2022

Yale University, Karolinska Institute Researchers Advance Spatial Chromatin Accessibility Profiling
Premium

Aug 12, 2022

Illumina Lowers 2022 Guidance, Braces for Fines from European Commission
Premium

Aug 10, 2022

Singular Genomics G4 Instrument Rollout Delayed Due to Supply Chain Issues
Premium

Jul 12, 2022

Ultima Genomics, Regeneron Pharmaceuticals Ink Development Agreement

Jun 27, 2022

UC Santa Cruz Spinout ClaretBio Pursues NGS Sample Prep Market With Focus on cfDNA, FFPE
Premium

Jun 16, 2022

Rady Children's Institute for Genomic Medicine Partners With Inozyme Pharma on NGS Newborn Screening

Jun 15, 2022

Thermo Fisher Scientific Receives CE-IVD Mark for NGS Aneuploidy Diagnostic Software Workflows

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.